Walgreens Boots Alliance (NASDAQ:WBA) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday.
A number of other research analysts also recently weighed in on WBA. Barclays assumed coverage on shares of Walgreens Boots Alliance in a research report on Thursday, March 8th. They issued an “equal weight” rating and a $76.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $88.00 target price (up previously from $86.00) on shares of Walgreens Boots Alliance in a research report on Wednesday, January 10th. Bank of America assumed coverage on shares of Walgreens Boots Alliance in a research note on Tuesday, February 27th. They issued a “neutral” rating and a $76.00 price target for the company. Vetr cut shares of Walgreens Boots Alliance from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 1st. Finally, Zacks Investment Research cut shares of Walgreens Boots Alliance from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Walgreens Boots Alliance currently has an average rating of “Buy” and an average target price of $84.45.
Walgreens Boots Alliance stock opened at $65.43 on Thursday. The firm has a market cap of $65,651.63, a price-to-earnings ratio of 18.07, a P/E/G ratio of 1.09 and a beta of 1.21. Walgreens Boots Alliance has a 12-month low of $63.82 and a 12-month high of $87.79. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.96 and a quick ratio of 0.47.
Walgreens Boots Alliance (NASDAQ:WBA) last released its earnings results on Thursday, January 4th. The pharmacy operator reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.01. The business had revenue of $30.74 billion during the quarter, compared to the consensus estimate of $30.39 billion. Walgreens Boots Alliance had a net margin of 3.19% and a return on equity of 19.15%. The firm’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.10 earnings per share. equities analysts forecast that Walgreens Boots Alliance will post 5.79 EPS for the current year.
In related news, insider Stefano Pessina bought 98,858 shares of the business’s stock in a transaction dated Monday, January 15th. The stock was bought at an average price of $76.07 per share, for a total transaction of $7,520,128.06. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 14.80% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of WBA. Arrowstreet Capital Limited Partnership raised its stake in Walgreens Boots Alliance by 675.5% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,891,845 shares of the pharmacy operator’s stock worth $427,866,000 after purchasing an additional 5,132,140 shares in the last quarter. LSV Asset Management raised its stake in Walgreens Boots Alliance by 38,624.0% in the 4th quarter. LSV Asset Management now owns 3,678,780 shares of the pharmacy operator’s stock worth $267,153,000 after purchasing an additional 3,669,280 shares in the last quarter. Two Sigma Advisers LP raised its stake in Walgreens Boots Alliance by 315.6% in the 4th quarter. Two Sigma Advisers LP now owns 2,639,155 shares of the pharmacy operator’s stock worth $191,655,000 after purchasing an additional 2,004,131 shares in the last quarter. CI Global Investments Inc. raised its stake in Walgreens Boots Alliance by 32.0% in the 4th quarter. CI Global Investments Inc. now owns 7,373,589 shares of the pharmacy operator’s stock worth $535,470,000 after purchasing an additional 1,785,449 shares in the last quarter. Finally, Glenview Capital Management LLC acquired a new stake in Walgreens Boots Alliance in the 2nd quarter worth about $136,875,000. Institutional investors own 60.93% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Walgreens Boots Alliance (WBA) Rating Lowered to Strong Sell at BidaskClub” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/03/24/walgreens-boots-alliance-wba-rating-lowered-to-strong-sell-at-bidaskclub.html.
About Walgreens Boots Alliance
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.